IRVINE, Calif., June 7, 2006 (PRIMEZONE) -- "It's not just Magic Johnson, a flourishing celebrity, who has survived and prospered despite his epic announcement fifteen years ago that he had contracted HIV," stated SmallCap Sentinel analyst D.R. Clark. "It's a legion of infected patients who, if infected just a few years earlier, would have been handed a virtual death warrant with their positive test results. Now amid the ever-improving drug cocktails first concocted in the mid-1990's, the battle is on to other venues, both literally and figuratively. We've come a long way since the disease was 'discovered' 25 years ago."
"And while we try to find ways to take first-world successes to the malignant poverty of Africa, companies are endeavoring to find better treatments and dare I say, vaccines and cures," Clark added. "Just last week, Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced preliminary results showing antiviral activity in only 10 days with its Phase II 10-Day Monotherapy study where SP-01A, an oral entry inhibitor, was tested 'alone' in patients experiencing HIV drug resistance."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs," is available at www.SmallCapSentinel.com and addresses emergent and established biotech companies including Samaritan, BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), Hana Biosciences Inc. (Nasdaq:HNAB), and The Immune Response Corporation (OTCBB:IMNR).
Samaritan is a drug development company driven to discover, develop and commercialize new, innovative drugs for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan is currently advancing eight promising compounds out of its rich pipeline of 250 possible drug candidates, all of which have the potential to create revenue-generating opportunities.
A free informational report regarding Samaritan is available here: http://stockupticks.com/profiles/3-15-06.html
A Research Report on Samaritan Pharmaceuticals can be downloaded here: http://www.shareholder.com/samaritan/reports.cfm
Individuals may also register to receive future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCapSentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy or offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as the basis for investment decisions. MP is not an investment advisor and this report is not investment advice. MP was paid $14,250 and will receive an additional $4,750 from Samaritan Pharmaceuticals for preparation of this profile and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.